No abstract available.
Neck* ; Urinary Bladder* ; Urinary Incontinence*

The concurrence of typical carcinoid admixed with adenocarcinoma of the gastrointestinal tract is a well known but unusual phenomenom that has been reported in the esophagus, stomach, gall bladder, colon and appendix. The amine precursor uptake and decarboxylation (APUD) concept included the idea that neuroendocrine cells of the gastrointestinal tract were dervied from the neural crest by a process of migration during embryogenesis. However the intimate admixture of cells which have morphologic and immunocytochemical properties of both carcinoid tumors and adenocarcinoma suggests that these tumors are derived from a multipotential stem cell showing bidirectional differentiation rather than from unrelated cell lines. The term composite carcinoma-carcinoid tumor is therefore an appropriate designation for these neoplasms. We report a case of composite carcinoma-carcinoid tumor of the stomach in a 38 year-old female with brief review of literature.
Female ; Humans ; Adenocarcinoma

The accessory ovary can be defined as an extraovarian tissue that is located near the normal ovaries and is connected to the broad ligament, infundibulopelvic ligament or utero-ovarian ligament. It has very rarely been reported. The majority was found during abdominopelvic surgeries for any other purposes, because they were usually small and less than 1 cm in diameter adn gave no particular symptoms related simply to their presence. We reported a case of accessory ovary in which developed a simple cyst of a largest diameter of 12 cm, and discussed the significance of the accessory ovary in clinical and pathological aspects.
Cysts

No abstract available.
Genitalia* ; Humans ; Male*

PURPOSE: It is well recognized that the incidence of sexual dysfunction in men increases with age. But the impact of lower urinary tract symptom (LUTS) on sexual dysfunction had not been widely studied. We aimed to ascertain the degree of correlation among sexual dysfunction, LUTS and age. MATERIALS AND METHODS: Between September 1998 and May 1999, 350 healthy Korean men over 50 years old living in Taegu and Kyungpook province were enrolled in the study. All of them completed IIEF (International Index of Erectile Function) 5-item questionnaire, International Prostatic Symptom Score(IPSS), digital rectal examination (DRE) and uroflowmetry. The IIEF, 5-item questionnaire consisted of erectile function (EF), sexual intercourse satisfaction (IS), orgasmic function (OF), sexual desire (SD) and overall satisfaction (OS). Each item was stratified into severe, moderate, mild and no dysfunction. Total men were stratified by IPSS, volume of prostate and maximal flow rate. RESULTS: The prevalence of sexual dysfunction was increased with age. The erectile function was decreased in men with severe symptoms (IPSS >20) in comparison to those without symptoms (IPSS <8). The erectile function and sexual intercourse satisfaction were decreased in men with large prostate (volume of prostate > 50gm) in comparison to those with normal prostate (volume of prostate < 21gm). The maximal flow rate was not correlated with sexual dysfunction. CONCLUSIONS: There was a significant number of patients with LUTS who have sexual dysfunction. A trend of increasing sexual dysfunction with increasing after urinary symptom severity and volume of prostate was fond. It is valuable to compare the sexual function after treatment of LUTS with it before treatment.
Coitus ; Daegu ; Digital Rectal Examination ; Gyeongsangbuk-do ; Humans ; Incidence ; Male ; Middle Aged ; Orgasm ; Prevalence ; Prostate ; Surveys and Questionnaires ; Urinary Tract*

PURPOSE: Intracavernosal self-injection therapy is now being used widely to treat erectile dysfunction. Although several intracavernosal therapies are available, their efficacy and safety have not been studied systematically. We investigates the efficacy and safety of intracavernosal injection of alprostadil (PGE1 ) in patients with erectile dysfunction. MATERIALS AND METHODS: From June 1996 to March 1998, 181 patients with erectile dysfunction were included in this study. Each patient was treated initially with 10micro gram of PGE1 . If the result of the injection was unsatisfactory, 20 micro gram of PGE1 was administered. The erection was evaluated clinically by manual palpation and estimated on a 5-point scale as no response, some enlargement, full enlargement, erection sufficient for intercourse, and full rigidity. In addition, each patient assessed his satisfaction with the treatment using a 3-point scale as poor, fair or good. The erectile dysfunction was classified as psychogenic, vascular, diabetic, neurogenic, or undetermined. To determine possible side effects, penile pain, hematoma, prolonged erection, priapism, and so forth were recorded by a questionnaire. RESULTS: Of the 181 men in this study, 60 (33.2%), 45 (24.9%), 42 (23.2%), 14 (7.7%), and 20 (11.0%) were judged to have psychogenic, vascular, diabetic, neurogenic, and undetermined causes of erectile dysfunction, respectively. A good erectile response to PGE1 was seen in 59 (98.4%), 38 (84.4%), 37 (88.1%), 13 (92.9%), and 16 (80%), respectively, of the patients in these groups. Satisfaction with the treatment was reported by 59 (98.3%), 39 (86.6%), 38 (90.5%), 13 (90%) patients. Only three drug-related side effects were observed: penile pain in 54 patients (33.5%), hematoma in 5 (2.8%), and prolonged erection in 4 (2.4%). Nevertheless, the dropout rate was 46% (83/181). The causes of discontinuation within 3 months were absence of sexual partner (8.8%), recovery of erectile function (9.5%), difficulty of manipulation (19.3%), needle phobia (22.7%), pain (21.5%), and economic status (18.2%). CONCLUSIONS: PGE1 was highly effective at producing an erection satisfactory for vaginal intercourse. The response rate was higher in psychogenic and neurogenic impotence than in vascular and diabetic impotence. Given the freedom from adverse effects such as fibrotic plaques, priapism, and liver dysfunction, PGE1 seems to be a preferable alternative to other drugs for intracavernosal injection therapy and is currently the only FDA-approved drug for this purpose. However, the dropout rate was high. Dilated attention to the procedure and careful follow-up are crucial to achieve maximal success and decrease the dropout rate.
Alprostadil* ; Erectile Dysfunction* ; Freedom ; Hematoma ; Humans ; Liver Diseases ; Male ; Needles ; Palpation ; Patient Dropouts ; Phobic Disorders ; Priapism ; Surveys and Questionnaires ; Sexual Partners

No abstract available.
Ligaments*

No abstract available.
Plasmapheresis* ; Postpartum Period* ; Pregnancy*

No abstract available.
Cause of Death* ; Kidney Transplantation* ; Kidney*

No abstract available.
Graft Survival* ; Humans ; Living Donors* ; Risk Factors* ; Transplants*